Abstract:Kehua Jiang, 1 Qing Wang, 1 Xiao-Long Chen, 1 Xiaodong Wang, 1 Xiaoya Gu, 1 Shuangshuang Feng, 1 Jian Wu, 2 Haojie Shang, 2 Xiaozhuo Ba, 2 Yanlong Zhang, 1 Kun Tang 2 1 Department of Urology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, People's Republic of China; 2 Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China Correspondence: Yanlong Zhang, Department of Urology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, People's Republic of China, Email Kun Tang, Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Avenue, Qiaokou District, Wuhan, 430030, People's Republic of China, Email Tryptophan (Trp) metabolism plays a vital role in cancer immunity. Indoleamine 2.3-dioxygenase 1 (IDO1), is a crucial enzyme in the metabolic pathway by which Trp is degraded to kynurenine (Kyn). IDO1-mediated Trp metabolites can inhibit tumor immunity and facilitate immune evasion by cancer cells; thus, targeting IDO1 is a potential tumor immunotherapy strategy. Recently, numerous IDO1 inhibitors have been introduced into clinical trials as immunotherapeutic agents for cancer treatment. However, drawbacks such as low oral bioavailability, slow onset of action, and high toxicity are associated with these drugs. With the continuous development of nanotechnology, medicine is gradually entering an era of precision healthcare. Nanodrugs carried by inorganic, lipid, and polymer nanoparticles (NPs) have shown great potential for tumor therapy, providing new ways to overcome tumor diversity and improve therapeutic efficacy. Compared to traditional drugs, nanomedicines offer numerous significant advantages, including a prolonged half-life, low toxicity, targeted delivery, and responsive release. Moreover, based on the physicochemical properties of these nanomaterials (eg, photothermal, ultrasonic response, and chemocatalytic properties), various combination therapeutic strategies have been developed to synergize the effects of IDO1 inhibitors and enhance their anticancer efficacy. This review is an overview of the mechanism by which the Trp-IDO1-Kyn pathway acts in tumor immune escape. The classification of IDO1 inhibitors, their clinical applications, and barriers for translational development are discussed, the use of IDO1 inhibitor-based nanodrug delivery systems as combination therapy strategies is summarized, and the issues faced in their clinical application are elucidated. We expect that this review will provide guidance for the development of IDO1 inhibitor-based nanoparticle nanomedicines that can overcome the limitations of current treatments, improve the efficacy of cancer immunotherapy, and lead to new breakthroughs in the field of cancer immunotherapy. Keywords: indoleamine 2, 3-dioxygenase 1, IDO1, IDO1 inhibitors, nanodrugs, nanodelivery, cancer immunotherapy, combination therapy Cancer, as a highly heterogeneous and complex systemic disease, 1 has continuously increased in its global incidence and mortality rates in recent years. The relatively weak immunogenicity of cancer endows it with a "protective shield" during development, allowing it to evade recognition and attack by the immune system. 2,3 The conventional treatment modalities for tumors; surgery, radiotherapy, and chemotherapy, are associated with several drawbacks: surgery may lead to trauma and the risk of recurrence, radiotherapy may induce severe toxic side effects and tolerance issues, and chemotherapy often results in adverse reaction events and drug resistance. In addition, these treatments have limited effectiveness in treating patients with advanced metastatic cancer. These factors render cancer one of the most challenging and difficult-to-cure diseases. The emergence of cancer immunotherapy has brought new hope for cancer cure. This type of therapy can activate and train both the intrinsic and adaptive immune systems to recognize and remove cancer cells while building a longer-lasting anti-tumor immune memory. 4 Compared with traditional cancer treatment strategies, cancer immunotherapy not only shows lower toxicity and fewer side effects, but also reduces the physical burden of patients. In addition, personalized treatment plans can be designed based on factors such as the patient's immune status and tumor type, especially in advanced cancer patients for whom conventional treatment may not achieve the expected results. Cancer immunotherapy offers new treatment options for such patients. 5 Several immunotherapy treatments have been clinically validated as effective against cancer -Abstract Truncated-

Development of a DNA Aptamer Targeting IDO1 with Anti-Tumor Effects.

IDO1: An important immunotherapy target in cancer treatment

Discovery of IDO1 and DNA Dual Targeting Antitumor Agents

Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy

Tumor and Dendritic Cell Dual-Targeting Nanocarriers Maximize the Therapeutic Potential of IDO1 Inhibitor in Vivo

Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy

Discovery of a potent apo-IDO1 inhibitor for cancer immunotherapy

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Off-tumor IDO1 Target Engagements Determine the Cancer-Immune Set Point and Predict the Immunotherapeutic Efficacy

IDO1 Inhibition Promotes Activation of Tumor-intrinsic STAT3 Pathway and Induces Adverse Tumor-protective Effects

Apo-Form Selective Inhibition of IDO for Tumor Immunotherapy

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

Nanoenabled Reversal of IDO1-Mediated Immunosuppression Synergizes with Immunogenic Chemotherapy for Improved Cancer Therapy.

Progress in Development of Small Molecule Inhibitors Targeting Indoleamine 2,3-Dioxygenase

Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective

Identification of a Compound Inhibiting Both the Enzymatic and Nonenzymatic Functions of Indoleamine 2,3-Dioxygenase 1

Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference.

Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies

Design, synthesis and biological evaluation of bicyclic carboxylic acid derivatives as IDO1 inhibitors

Synthesis and in Vivo Antitumor Evaluation of an Orally Active Potent Phosphonamidate Derivative Targeting IDO1/IDO2/TDO

D-MT prompts the anti-tumor effect of oxaliplatin by inhibiting IDO expression in a mouse model of colon cancer